Senzime AB (publ) (OM: SEZI)
Health Care · Health Care Equipment & Supplies · SE
Skr2.80
-4.11% today · -52.1% 1Y
Senzime AB (publ) (OM: SEZI) operates in the Health Care Equipment & Supplies industry within the Health Care sector. The company is valued at $45.91M and employs 59 people.
Over the last twelve months the share price has lost 52.1%, trading between 2.35 and 6.24.
Tweenvest scores Senzime AB (publ) across four factors: quality 41/100, value 51/100, growth 100/100. Its strongest factor is growth.
SEZI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $45.91M
- Revenue (TTM)
- $10.60M
- P/E
- —
- EPS
- -0.71
- Dividend yield
- —
- Beta (5Y)
- 0.43
- 52-week high
- Skr6.24
- 52-week low
- Skr2.35
- Avg volume (3M)
- —
- Shares outstanding
- 157.22M
- Employees
- 59
- Next earnings
- —
About Senzime AB (publ)
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
- ISIN
- SE0002478776
- Founded
- 1999
- Listed since
- Jun 18, 2008
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Health Care Equipment & Supplies companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim SirketiIBSE: MEDTR | $47.32M | TL19.62 | +6.05% |
| Modulight OyjHLSE: MODU | $47.29M | €0.99 | 0.00% |
| Svas Biosana S.p.A.BIT: SVS | $46.78M | €8.00 | +2.56% |
| DRTECH CorporationKOSDAQ: A214680 | $46.69M | ₩3,760.00 | -3.96% |
| AViTA CorporationTPEX: 4735 | $45.82M | NT$38.05 | +5.69% |
| Xtant Medical Holdings, Inc.NYSEAM: XTNT | $45.73M | $0.32 | -1.84% |
| BrainCool AB (publ)OM: BRAIN | $44.78M | Skr1.10 | -3.00% |
| Epiminder LimitedASX: EPI | $44.60M | AU$0.30 | +13.46% |
Figures last refreshed Oct 11, 2026.